Headache and Migraine

Despite not meeting its primary efficacy end point for preventive treatment of episodic migraine, onabotulinumtoxinA was well tolerated and safety outcomes were consistent with prior data.

A new study reveals that early treatment with the Nerivio wearable significantly enhances migraine relief, doubling efficacy outcomes for patients.

A physician assistant who specializes in neurology previewed her upcoming presentation on evaluating patients with headache at the 2025 Baptist Miami Neuroscience Symposium.

Salvia BioElectronics’ PRIMUS system, currently being assessed in a clinical trial, delivers subcutaneous occipital and supraorbital nerve stimulation for patients with resistant migraine.

In a recent randomized clinical trial, a smartphone-based relaxation technique provided to patients presenting to the emergency department was associated with reduced migraine-related disability.

At AHS 2025, Eric Baron, DO, headache specialist at Cleveland Clinic, presented findings from a cross-sectional survey that examined psychedelic use among Canadian patients with migraine and cluster headache.

Here's some of what is coming soon to NeurologyLive® this week.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on care of trigeminal neuralgia.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 19, 2025.

ShiraTronics reveals promising 12-month results from its neuromodulation device, showing significant migraine relief and improved quality of life for chronic migraine patients.

At AHS 2025, the assistant professor of neurology at Wake Forest Baptist Atrium Health discussed clinical interventions for women with enlarged breast who experience headache. [WATCH TIME: 4 minutes]

The vice chair of neurology at West Virginia University outlined key challenges in academic neurology and reflected on the evolving responsibilities of vice chairs in supporting departmental growth and leadership. [WATCH TIME: 3 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 12, 2025.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Patricia Pozo-Rosich, MD, PhD. [LISTEN TIME: 19 minutes]

Tamara Kaplan, MD, vice chair of education for the department of neurology at Mass General Brigham, shares insights on evolving neurology education, highlighting her framework for supporting clinician educators and the growing recognition of education as a career path.

The vice chair of neurology at West Virginia University reflected on receiving the AUPN Leadership Award, addressing challenges in academic neurology and the evolving responsibilities of vice chairs in advancing departmental goals.

A new qualitative study of 20 patients with migraine explored and documented the prodrome phase, revealing some of their common symptoms and timing before headache onset.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 5, 2025.

The head of the neurology department at Vall d’Hebron University Hospital provided perspective on how migraine treatment might advance in the near future, highlighting emerging pathways like PACAP antagonists and long-acting toxins. [WATCH TIME: 3 minutes]

Amaal Starling, MD, FAHS, FAAN, associate professor of neurology at Mayo Clinic College of Medicine, shared data recently presented at AHS 2025 showing that eptinezumab extended the time between migraine attacks.

Neurology News Network. for the week ending August 30, 2025. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 29, 2025.

The head of the neurology department at the Vall d’Hebron University Hospital shared thoughts and perspectives on significance of fremanezumab’s recently expanded approval, calling it a long-awaited breakthrough for treating pediatric migraine. [WATCH TIME: 3 minutes]